{"id":"etanercept-methotrexate","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"5-10","effect":"Infections (including serious infections)"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-15","effect":"Elevated liver enzymes"},{"rate":"2-5","effect":"Cytopenias (anemia, leukopenia, thrombocytopenia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept is a TNF receptor fusion protein that binds and neutralizes TNF-alpha, a key inflammatory cytokine. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase and reduces proliferation of immune cells. The combination provides complementary anti-inflammatory effects, with methotrexate enhancing etanercept's efficacy and reducing the risk of antibody formation against the biologic.","oneSentence":"Etanercept blocks tumor necrosis factor (TNF) to reduce inflammation, while methotrexate suppresses immune cell proliferation; together they synergistically reduce joint inflammation and slow disease progression in rheumatoid arthritis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:48.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe, active disease)"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT03649061","phase":"PHASE4","title":"COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2018-06-08","conditions":"Arthritis, Rheumatoid","enrollment":276},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT03728478","phase":"PHASE3","title":"STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS","status":"RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2019-05-29","conditions":"Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative","enrollment":260},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT01903317","phase":"","title":"Evaluation of Vitamin D Levels in Psoriasis Patients","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2013-06","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT00393471","phase":"PHASE3","title":"Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Active Rheumatoid Arthritis","enrollment":615},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT00783536","phase":"PHASE4","title":"A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":"Psoriasis","enrollment":3500},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT03781375","phase":"PHASE3","title":"Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2000-08-24","conditions":"Juvenile Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02115750","phase":"PHASE3","title":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":647},{"nctId":"NCT03813771","phase":"PHASE4","title":"Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2019-03","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT02313922","phase":"PHASE4","title":"Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2014-11","conditions":"Psoriasis","enrollment":466},{"nctId":"NCT02242474","phase":"PHASE4","title":"Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":660},{"nctId":"NCT02715908","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":148},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT03352622","phase":"NA","title":"Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Universidad de Antioquia","startDate":"2017-10-17","conditions":"Pharmacological Action","enrollment":372},{"nctId":"NCT01927757","phase":"PHASE4","title":"Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-05-06","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT03403140","phase":"PHASE3","title":"Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2016-10-06","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT03332719","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Gema Biotech S.A.","startDate":"2016-02","conditions":"Rheumatoid Arthritis","enrollment":168},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT01895309","phase":"PHASE3","title":"A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":596},{"nctId":"NCT01812954","phase":"","title":"Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis","status":"COMPLETED","sponsor":"Jochen Schmitt.","startDate":"2013-03","conditions":"Psoriasis","enrollment":1},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT01313208","phase":"PHASE4","title":"Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT02109289","phase":"PHASE4","title":"Etanercept in Rheumatoid Arthritis and Vascular Inflammation","status":"TERMINATED","sponsor":"Innovaderm Research Inc.","startDate":"2014-04","conditions":"Rheumatoid Arthritis, Vascular Inflammation","enrollment":5},{"nctId":"NCT01558089","phase":"","title":"Good EULAR Response In Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":76},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01578850","phase":"PHASE4","title":"Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":491},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT01783015","phase":"PHASE4","title":"Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT02357069","phase":"PHASE3","title":"A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2015-02","conditions":"Arthritis, Rheumatoid","enrollment":372},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Psoriasis","enrollment":593},{"nctId":"NCT00688103","phase":"PHASE4","title":"Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan","status":"COMPLETED","sponsor":"Japan Biological Agent Study Integrated Consortium","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":151},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT00565409","phase":"PHASE4","title":"Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Arthritis, Rheumatoid","enrollment":834},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT02376478","phase":"","title":"On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-12","conditions":"Psoriasis, Inflammatory Bowel Diseases","enrollment":222},{"nctId":"NCT01646385","phase":"","title":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":6393},{"nctId":"NCT00654368","phase":"PHASE4","title":"CAMEO: Canadian Methotrexate and Etanercept Outcome Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Rheumatoid Arthritis","enrollment":258},{"nctId":"NCT00259610","phase":"PHASE4","title":"Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":755},{"nctId":"NCT00913458","phase":"PHASE4","title":"Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Active Rheumatoid Arthritis, Arthritis, Rheumatoid, Rheumatoid Arthritis","enrollment":306},{"nctId":"NCT01270997","phase":"PHASE3","title":"Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":294},{"nctId":"NCT00405275","phase":"NA","title":"Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2007-07","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT01557322","phase":"","title":"Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Rheumatoid Arthritis","enrollment":1754},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT00858780","phase":"PHASE4","title":"Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT01001208","phase":"PHASE3","title":"The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11","conditions":"Psoriasis","enrollment":478},{"nctId":"NCT00035958","phase":"PHASE2, PHASE3","title":"Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2002-08","conditions":"Dermatomyositis","enrollment":75},{"nctId":"NCT00443430","phase":"PHASE4","title":"Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2007-05","conditions":"Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT00115219","phase":"PHASE4","title":"Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00078793","phase":"","title":"Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-06","conditions":"Juvenile Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT00244556","phase":"PHASE4","title":"Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00520572","phase":"PHASE2","title":"A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-08","conditions":"Rheumatoid Arthritis","enrollment":385},{"nctId":"NCT00195494","phase":"PHASE4","title":"Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-11","conditions":"Rheumatoid Arthritis","enrollment":542},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00713544","phase":"PHASE2","title":"A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Rheumatoid Arthritis","enrollment":373},{"nctId":"NCT00445770","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-07","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT00252668","phase":"PHASE4","title":"Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00931957","phase":"NA","title":"Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2010-10","conditions":"Behcet Syndrome, Uveal Disease","enrollment":80},{"nctId":"NCT00422227","phase":"PHASE4","title":"Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00161655","phase":"PHASE4","title":"Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-04","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":60},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00001901","phase":"PHASE2","title":"Etanercept to Treat Wegener's Granulomatosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-02","conditions":"Vasculitis, Wegener's Granulomatosis","enrollment":60},{"nctId":"NCT00443950","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-06","conditions":"Arthritis, Rheumatoid","enrollment":150},{"nctId":"NCT00523692","phase":"PHASE4","title":"Remission Induction in Very Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University Hospital Birmingham","startDate":"2007-09","conditions":"Rheumatoid Arthritis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Etanercept + Methotrexate","genericName":"Etanercept + Methotrexate","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept blocks tumor necrosis factor (TNF) to reduce inflammation, while methotrexate suppresses immune cell proliferation; together they synergistically reduce joint inflammation and slow disease progression in rheumatoid arthritis. Used for Rheumatoid arthritis (moderate to severe, active disease), Polyarticular juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}